Floatz logo

ab-1015

Ovarian Diseases

Arsenal Biosciences, Inc.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Ovarian Diseases cohort.

Asset / SponsorPhaseRating
Irinotecan
Xiaoxiang Chen
Phase 3BB
Carboplatin
Fujian Cancer Hospital
Phase 3BB
Inno-206
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3BB
Olaparib
Xiaoxiang Chen
Phase 2BB
Pembrolizumab
Sheba Medical Center
Phase 2B

View all 25 →

Same molecule, other indications

ab-1015 is also rated in:

ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
epithelial neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
female reproductive system neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →